Synonyms: compound 22c [PMID: 18975928] | MB-07811 | MB07811 | VK-2809
Compound class:
Synthetic organic
Comment: VK2809 (MB07811) was a first-in-class, liver-targeting, thyroid hormone receptor-β agonist prodrug that was intended to lower serum cholesterol and triglycerides as a novel treament for primary hypercholesterolemia and non-alcoholic fatty liver disease [2-5].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J et al.. (2008)
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem, 51 (22): 7075-93. [PMID:18975928] |
2. Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F. (2014)
Thyroid hormone analogues and derivatives: Actions in fatty liver. World J Hepatol, 6 (3): 114-29. [PMID:24672641] |
3. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD et al.. (2007)
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A, 104 (39): 15490-5. [PMID:17878314] |
4. Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL et al.. (2009)
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol, 156 (3): 454-65. [PMID:19183199] |
5. Wirth EK, Puengel T, Spranger J, Tacke F. (2022)
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. Expert Rev Endocrinol Metab, 17 (5): 425-434. [PMID:35957531] |